Phase 3
Completed N=598
Efficacy, Safety, and Immunogenicity of Subcutaneous DMB-3115 Versus Stelara® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Moderate to Severe Chronic Plaque Psoriasis
Source: ClinicalTrials.gov NCT04785326 ↗
Enrolled (actual)
598
Serious AEs
0.9%
Results posted
Jan 2024
Primary outcomePrimary: • To Evaluate Efficacy of DMB-3115 in Comparison With Stelara — 77.5; 77.85; 87.59; 87.89 percent change in PASI score
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
This study is designed to evaluate efficacy, safety, pharmacokinetics (PK) and immunogenicity of subcutaneously administered DMB-3115 in comparison with Stelara for treatment of moderate to severe chronic plaque psoriasis.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY • To Evaluate Efficacy of DMB-3115 in Comparison With Stelara |
77.5; 77.85; 87.59; 87.89 | — |
Eligibility Criteria
Inclusion Criteria
- Patients who have a diagnosis of plaque-type psoriasis for at least 6 months.
Exclusion Criteria
- Patients with hypersensitivity to ustekinumab or any of the product excipients.
Data sourced from ClinicalTrials.gov (NCT04785326). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.